Effectiveness of a monovalent rotavirus vaccine in infants in Malawi after programmatic roll-out: an observational and case-control study
Rotavirus is the main cause of severe acute gastroenteritis in children in Africa. Monovalent human rotavirus vaccine (RV1) was added into Malawi's infant immunisation schedule on Oct 29, 2012. We aimed to assess the impact and effectiveness of RV1 on rotavirus gastroenteritis in the 2 years af...
Saved in:
| Published in | The Lancet infectious diseases Vol. 15; no. 4; pp. 422 - 428 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Ltd
01.04.2015
Elsevier Limited Elsevier Science ;, The Lancet Pub. Group |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1473-3099 1474-4457 1474-4457 |
| DOI | 10.1016/S1473-3099(14)71060-6 |
Cover
| Abstract | Rotavirus is the main cause of severe acute gastroenteritis in children in Africa. Monovalent human rotavirus vaccine (RV1) was added into Malawi's infant immunisation schedule on Oct 29, 2012. We aimed to assess the impact and effectiveness of RV1 on rotavirus gastroenteritis in the 2 years after introduction.
From Jan 1, 2012, to June 30, 2014, we recruited children younger than 5 years who were admitted into Queen Elizabeth Central Hospital, Blantyre, Malawi, with acute gastroenteritis. We assessed stool samples from these children for presence of rotavirus with use of ELISA and we genotyped rotaviruses with use of RT-PCR. We compared rotavirus detection rates in stool samples and incidence of hospital admittance for rotavirus in children from Jan 1 to June 30, in the year before vaccination (2012) with the same months in the 2 years after vaccination was introduced (2013 and 2014). In the case-control portion of our study, we recruited eligible rotavirus-positive children from the surveillance platform and calculated vaccine effectiveness (one minus the odds ratio of vaccination) by comparing infants with rotavirus gastroenteritis with infants who tested negative for rotavirus, and with community age-matched and neighbourhood-matched controls.
We enrolled 1431 children, from whom we obtained 1417 stool samples (99%). We detected rotavirus in 79 of 157 infants (50%) before the vaccine, compared with 57 of 219 (40%) and 52 of 170 (31%) in successive calendar years after vaccine introduction (p=0·0002). In the first half of 2012, incidence of rotavirus hospital admission was 269 per 100 000 infants compared with 284 in the same months of 2013 (rise of 5·8%, 95% CI −23·1 to 45·4; p=0·73) and 153 in these months in 2014 (a reduction from the prevaccine period of 43·2%, 18·0–60·7; p=0·003). We recruited 118 vaccine-eligible rotavirus cases (median age 8·9 months; IQR 6·6–11·1), 317 rotavirus-test-negative controls (9·4 months; 6·9–11·9), and 380 community controls (8·8 months; 6·5–11·1). Vaccine effectiveness for two doses of RV1 in rotavirus-negative individuals was 64% (95% CI 24–83) and community controls was 63% (23–83). The point estimate of effectiveness was higher against genotype G1 than against G2 and G12.
Routine use of RV1 reduced hospital admissions for several genotypes of rotavirus in children younger than 5 years, especially in infants younger than 1 year. Our data support introduction of rotavirus vaccination at the WHO recommended schedule, with continuing surveillance in high-mortality countries.
Wellcome Trust, GlaxoSmithKline Biologicals. |
|---|---|
| AbstractList | Rotavirus is the main cause of severe acute gastroenteritis in children in Africa. Monovalent human rotavirus vaccine (RV1) was added into Malawi's infant immunisation schedule on Oct 29, 2012. We aimed to assess the impact and effectiveness of RV1 on rotavirus gastroenteritis in the 2 years after introduction.
From Jan 1, 2012, to June 30, 2014, we recruited children younger than 5 years who were admitted into Queen Elizabeth Central Hospital, Blantyre, Malawi, with acute gastroenteritis. We assessed stool samples from these children for presence of rotavirus with use of ELISA and we genotyped rotaviruses with use of RT-PCR. We compared rotavirus detection rates in stool samples and incidence of hospital admittance for rotavirus in children from Jan 1 to June 30, in the year before vaccination (2012) with the same months in the 2 years after vaccination was introduced (2013 and 2014). In the case-control portion of our study, we recruited eligible rotavirus-positive children from the surveillance platform and calculated vaccine effectiveness (one minus the odds ratio of vaccination) by comparing infants with rotavirus gastroenteritis with infants who tested negative for rotavirus, and with community age-matched and neighbourhood-matched controls.
We enrolled 1431 children, from whom we obtained 1417 stool samples (99%). We detected rotavirus in 79 of 157 infants (50%) before the vaccine, compared with 57 of 219 (40%) and 52 of 170 (31%) in successive calendar years after vaccine introduction (p=0·0002). In the first half of 2012, incidence of rotavirus hospital admission was 269 per 100,000 infants compared with 284 in the same months of 2013 (rise of 5·8%, 95% CI -23·1 to 45·4; p=0·73) and 153 in these months in 2014 (a reduction from the prevaccine period of 43·2%, 18·0-60·7; p=0·003). We recruited 118 vaccine-eligible rotavirus cases (median age 8·9 months; IQR 6·6-11·1), 317 rotavirus-test-negative controls (9·4 months; 6·9-11·9), and 380 community controls (8·8 months; 6·5-11·1). Vaccine effectiveness for two doses of RV1 in rotavirus-negative individuals was 64% (95% CI 24-83) and community controls was 63% (23-83). The point estimate of effectiveness was higher against genotype G1 than against G2 and G12.
Routine use of RV1 reduced hospital admissions for several genotypes of rotavirus in children younger than 5 years, especially in infants younger than 1 year. Our data support introduction of rotavirus vaccination at the WHO recommended schedule, with continuing surveillance in high-mortality countries.
Wellcome Trust, GlaxoSmithKline Biologicals. Rotavirus is the main cause of severe acute gastroenteritis in children in Africa. Monovalent human rotavirus vaccine (RV1) was added into Malawi's infant immunisation schedule on Oct 29, 2012. We aimed to assess the impact and effectiveness of RV1 on rotavirus gastroenteritis in the 2 years after introduction.BACKGROUNDRotavirus is the main cause of severe acute gastroenteritis in children in Africa. Monovalent human rotavirus vaccine (RV1) was added into Malawi's infant immunisation schedule on Oct 29, 2012. We aimed to assess the impact and effectiveness of RV1 on rotavirus gastroenteritis in the 2 years after introduction.From Jan 1, 2012, to June 30, 2014, we recruited children younger than 5 years who were admitted into Queen Elizabeth Central Hospital, Blantyre, Malawi, with acute gastroenteritis. We assessed stool samples from these children for presence of rotavirus with use of ELISA and we genotyped rotaviruses with use of RT-PCR. We compared rotavirus detection rates in stool samples and incidence of hospital admittance for rotavirus in children from Jan 1 to June 30, in the year before vaccination (2012) with the same months in the 2 years after vaccination was introduced (2013 and 2014). In the case-control portion of our study, we recruited eligible rotavirus-positive children from the surveillance platform and calculated vaccine effectiveness (one minus the odds ratio of vaccination) by comparing infants with rotavirus gastroenteritis with infants who tested negative for rotavirus, and with community age-matched and neighbourhood-matched controls.METHODSFrom Jan 1, 2012, to June 30, 2014, we recruited children younger than 5 years who were admitted into Queen Elizabeth Central Hospital, Blantyre, Malawi, with acute gastroenteritis. We assessed stool samples from these children for presence of rotavirus with use of ELISA and we genotyped rotaviruses with use of RT-PCR. We compared rotavirus detection rates in stool samples and incidence of hospital admittance for rotavirus in children from Jan 1 to June 30, in the year before vaccination (2012) with the same months in the 2 years after vaccination was introduced (2013 and 2014). In the case-control portion of our study, we recruited eligible rotavirus-positive children from the surveillance platform and calculated vaccine effectiveness (one minus the odds ratio of vaccination) by comparing infants with rotavirus gastroenteritis with infants who tested negative for rotavirus, and with community age-matched and neighbourhood-matched controls.We enrolled 1431 children, from whom we obtained 1417 stool samples (99%). We detected rotavirus in 79 of 157 infants (50%) before the vaccine, compared with 57 of 219 (40%) and 52 of 170 (31%) in successive calendar years after vaccine introduction (p=0·0002). In the first half of 2012, incidence of rotavirus hospital admission was 269 per 100,000 infants compared with 284 in the same months of 2013 (rise of 5·8%, 95% CI -23·1 to 45·4; p=0·73) and 153 in these months in 2014 (a reduction from the prevaccine period of 43·2%, 18·0-60·7; p=0·003). We recruited 118 vaccine-eligible rotavirus cases (median age 8·9 months; IQR 6·6-11·1), 317 rotavirus-test-negative controls (9·4 months; 6·9-11·9), and 380 community controls (8·8 months; 6·5-11·1). Vaccine effectiveness for two doses of RV1 in rotavirus-negative individuals was 64% (95% CI 24-83) and community controls was 63% (23-83). The point estimate of effectiveness was higher against genotype G1 than against G2 and G12.FINDINGSWe enrolled 1431 children, from whom we obtained 1417 stool samples (99%). We detected rotavirus in 79 of 157 infants (50%) before the vaccine, compared with 57 of 219 (40%) and 52 of 170 (31%) in successive calendar years after vaccine introduction (p=0·0002). In the first half of 2012, incidence of rotavirus hospital admission was 269 per 100,000 infants compared with 284 in the same months of 2013 (rise of 5·8%, 95% CI -23·1 to 45·4; p=0·73) and 153 in these months in 2014 (a reduction from the prevaccine period of 43·2%, 18·0-60·7; p=0·003). We recruited 118 vaccine-eligible rotavirus cases (median age 8·9 months; IQR 6·6-11·1), 317 rotavirus-test-negative controls (9·4 months; 6·9-11·9), and 380 community controls (8·8 months; 6·5-11·1). Vaccine effectiveness for two doses of RV1 in rotavirus-negative individuals was 64% (95% CI 24-83) and community controls was 63% (23-83). The point estimate of effectiveness was higher against genotype G1 than against G2 and G12.Routine use of RV1 reduced hospital admissions for several genotypes of rotavirus in children younger than 5 years, especially in infants younger than 1 year. Our data support introduction of rotavirus vaccination at the WHO recommended schedule, with continuing surveillance in high-mortality countries.INTERPRETATIONRoutine use of RV1 reduced hospital admissions for several genotypes of rotavirus in children younger than 5 years, especially in infants younger than 1 year. Our data support introduction of rotavirus vaccination at the WHO recommended schedule, with continuing surveillance in high-mortality countries.Wellcome Trust, GlaxoSmithKline Biologicals.FUNDINGWellcome Trust, GlaxoSmithKline Biologicals. Summary Background Rotavirus is the main cause of severe acute gastroenteritis in children in Africa. Monovalent human rotavirus vaccine (RV1) was added into Malawi's infant immunisation schedule on Oct 29, 2012. We aimed to assess the impact and effectiveness of RV1 on rotavirus gastroenteritis in the 2 years after introduction. Methods From Jan 1, 2012, to June 30, 2014, we recruited children younger than 5 years who were admitted into Queen Elizabeth Central Hospital, Blantyre, Malawi, with acute gastroenteritis. We assessed stool samples from these children for presence of rotavirus with use of ELISA and we genotyped rotaviruses with use of RT-PCR. We compared rotavirus detection rates in stool samples and incidence of hospital admittance for rotavirus in children from Jan 1 to June 30, in the year before vaccination (2012) with the same months in the 2 years after vaccination was introduced (2013 and 2014). In the case-control portion of our study, we recruited eligible rotavirus-positive children from the surveillance platform and calculated vaccine effectiveness (one minus the odds ratio of vaccination) by comparing infants with rotavirus gastroenteritis with infants who tested negative for rotavirus, and with community age-matched and neighbourhood-matched controls. Findings We enrolled 1431 children, from whom we obtained 1417 stool samples (99%). We detected rotavirus in 79 of 157 infants (50%) before the vaccine, compared with 57 of 219 (40%) and 52 of 170 (31%) in successive calendar years after vaccine introduction (p=0·0002). In the first half of 2012, incidence of rotavirus hospital admission was 269 per 100 000 infants compared with 284 in the same months of 2013 (rise of 5·8%, 95% CI −23·1 to 45·4; p=0·73) and 153 in these months in 2014 (a reduction from the prevaccine period of 43·2%, 18·0–60·7; p=0·003). We recruited 118 vaccine-eligible rotavirus cases (median age 8·9 months; IQR 6·6–11·1), 317 rotavirus-test-negative controls (9·4 months; 6·9–11·9), and 380 community controls (8·8 months; 6·5–11·1). Vaccine effectiveness for two doses of RV1 in rotavirus-negative individuals was 64% (95% CI 24–83) and community controls was 63% (23–83). The point estimate of effectiveness was higher against genotype G1 than against G2 and G12. Interpretation Routine use of RV1 reduced hospital admissions for several genotypes of rotavirus in children younger than 5 years, especially in infants younger than 1 year. Our data support introduction of rotavirus vaccination at the WHO recommended schedule, with continuing surveillance in high-mortality countries. Funding Wellcome Trust, GlaxoSmithKline Biologicals. Rotavirus is the main cause of severe acute gastroenteritis in children in Africa. Monovalent human rotavirus vaccine (RV1) was added into Malawi's infant immunisation schedule on Oct 29, 2012. We aimed to assess the impact and effectiveness of RV1 on rotavirus gastroenteritis in the 2 years after introduction. From Jan 1, 2012, to June 30, 2014, we recruited children younger than 5 years who were admitted into Queen Elizabeth Central Hospital, Blantyre, Malawi, with acute gastroenteritis. We assessed stool samples from these children for presence of rotavirus with use of ELISA and we genotyped rotaviruses with use of RT-PCR. We compared rotavirus detection rates in stool samples and incidence of hospital admittance for rotavirus in children from Jan 1 to June 30, in the year before vaccination (2012) with the same months in the 2 years after vaccination was introduced (2013 and 2014). In the case-control portion of our study, we recruited eligible rotavirus-positive children from the surveillance platform and calculated vaccine effectiveness (one minus the odds ratio of vaccination) by comparing infants with rotavirus gastroenteritis with infants who tested negative for rotavirus, and with community age-matched and neighbourhood-matched controls. We enrolled 1431 children, from whom we obtained 1417 stool samples (99%). We detected rotavirus in 79 of 157 infants (50%) before the vaccine, compared with 57 of 219 (40%) and 52 of 170 (31%) in successive calendar years after vaccine introduction (p=0·0002). In the first half of 2012, incidence of rotavirus hospital admission was 269 per 100 000 infants compared with 284 in the same months of 2013 (rise of 5·8%, 95% CI −23·1 to 45·4; p=0·73) and 153 in these months in 2014 (a reduction from the prevaccine period of 43·2%, 18·0–60·7; p=0·003). We recruited 118 vaccine-eligible rotavirus cases (median age 8·9 months; IQR 6·6–11·1), 317 rotavirus-test-negative controls (9·4 months; 6·9–11·9), and 380 community controls (8·8 months; 6·5–11·1). Vaccine effectiveness for two doses of RV1 in rotavirus-negative individuals was 64% (95% CI 24–83) and community controls was 63% (23–83). The point estimate of effectiveness was higher against genotype G1 than against G2 and G12. Routine use of RV1 reduced hospital admissions for several genotypes of rotavirus in children younger than 5 years, especially in infants younger than 1 year. Our data support introduction of rotavirus vaccination at the WHO recommended schedule, with continuing surveillance in high-mortality countries. Wellcome Trust, GlaxoSmithKline Biologicals. Background Rotavirus is the main cause of severe acute gastroenteritis in children in Africa. Monovalent human rotavirus vaccine (RV1) was added into Malawi's infant immunisation schedule on Oct 29, 2012. We aimed to assess the impact and effectiveness of RV1 on rotavirus gastroenteritis in the 2 years after introduction. Methods From Jan 1, 2012, to June 30, 2014, we recruited children younger than 5 years who were admitted into Queen Elizabeth Central Hospital, Blantyre, Malawi, with acute gastroenteritis. We assessed stool samples from these children for presence of rotavirus with use of ELISA and we genotyped rotaviruses with use of RT-PCR. We compared rotavirus detection rates in stool samples and incidence of hospital admittance for rotavirus in children from Jan 1 to June 30, in the year before vaccination (2012) with the same months in the 2 years after vaccination was introduced (2013 and 2014). In the case-control portion of our study, we recruited eligible rotavirus-positive children from the surveillance platform and calculated vaccine effectiveness (one minus the odds ratio of vaccination) by comparing infants with rotavirus gastroenteritis with infants who tested negative for rotavirus, and with community age-matched and neighbourhood-matched controls. Findings We enrolled 1431 children, from whom we obtained 1417 stool samples (99%). We detected rotavirus in 79 of 157 infants (50%) before the vaccine, compared with 57 of 219 (40%) and 52 of 170 (31%) in successive calendar years after vaccine introduction (p=0.0002). In the first half of 2012, incidence of rotavirus hospital admission was 269 per 100000 infants compared with 284 in the same months of 2013 (rise of 5.8%, 95% CI -23.1 to 45.4; p=0.73) and 153 in these months in 2014 (a reduction from the prevaccine period of 43.2%, 18.0-60.7; p=0.003). We recruited 118 vaccine-eligible rotavirus cases (median age 8.9 months; IQR 6.6-11.1), 317 rotavirus-test-negative controls (9.4 months; 6.9-11.9), and 380 community controls (8.8 months; 6.5-11.1). Vaccine effectiveness for two doses of RV1 in rotavirus-negative individuals was 64% (95% CI 24-83) and community controls was 63% (23-83). The point estimate of effectiveness was higher against genotype G1 than against G2 and G12. Interpretation Routine use of RV1 reduced hospital admissions for several genotypes of rotavirus in children younger than 5 years, especially in infants younger than 1 year. Our data support introduction of rotavirus vaccination at the WHO recommended schedule, with continuing surveillance in high-mortality countries. Funding Wellcome Trust, GlaxoSmithKline Biologicals. Rotavirus is the main cause of severe acute gastroenteritis in children in Africa. Monovalent human rotavirus vaccine (RV1) was added into Malawi's infant immunisation schedule on Oct 29, 2012. We aimed to assess the impact and effectiveness of RV1 on rotavirus gastroenteritis in the 2 years after introduction. Methods From Jan 1, 2012, to June 30, 2014, we recruited children younger than 5 years who were admitted into Queen Elizabeth Central Hospital, Blantyre, Malawi, with acute gastroenteritis. We assessed stool samples from these children for presence of rotavirus with use of ELISA and we genotyped rotaviruses with use of RT-PCR. We compared rotavirus detection rates in stool samples and incidence of hospital admittance for rotavirus in children from Jan 1 to June 30, in the year before vaccination (2012) with the same months in the 2 years after vaccination was introduced (2013 and 2014). In the case-control portion of our study, we recruited eligible rotavirus-positive children from the surveillance platform and calculated vaccine effectiveness (one minus the odds ratio of vaccination) by comparing infants with rotavirus gastroenteritis with infants who tested negative for rotavirus, and with community age-matched and neighbourhood-matched controls. Findings We enrolled 1431 children, from whom we obtained 1417 stool samples (99%). We detected rotavirus in 79 of 157 infants (50%) before the vaccine, compared with 57 of 219 (40%) and 52 of 170 (31%) in successive calendar years after vaccine introduction (p=0·0002). In the first half of 2012, incidence of rotavirus hospital admission was 269 per 100 000 infants compared with 284 in the same months of 2013 (rise of 5·8%, 95% CI -23·1 to 45·4; p=0·73) and 153 in these months in 2014 (a reduction from the prevaccine period of 43·2%, 18·0-60·7; p=0·003). We recruited 118 vaccine-eligible rotavirus cases (median age 8·9 months; IQR 6·6-11·1), 317 rotavirus-test-negative controls (9·4 months; 6·9-11·9), and 380 community controls (8·8 months; 6·5-11·1). Vaccine effectiveness for two doses of RV1 in rotavirus-negative individuals was 64% (95% CI 24-83) and community controls was 63% (23-83). The point estimate of effectiveness was higher against genotype G1 than against G2 and G12. Interpretation Routine use of RV1 reduced hospital admissions for several genotypes of rotavirus in children younger than 5 years, especially in infants younger than 1 year. Our data support introduction of rotavirus vaccination at the WHO recommended schedule, with continuing surveillance in high-mortality countries. Funding Wellcome Trust, GlaxoSmithKline Biologicals. |
| Author | Parashar, Umesh D Jere, Khuzwayo C Tate, Jacqueline E Bar-Zeev, Naor Kapanda, Lester Cunliffe, Nigel A Nakagomi, Osamu Mwansambo, Charles Heyderman, Robert S French, Neil Iturriza-Gomara, Miren Costello, Anthony |
| Author_xml | – sequence: 1 givenname: Naor surname: Bar-Zeev fullname: Bar-Zeev, Naor organization: Malawi-Liverpool-Wellcome Trust Clinical Research Programme, College of Medicine, University of Malawi, Blantyre, Malawi – sequence: 2 givenname: Lester surname: Kapanda fullname: Kapanda, Lester organization: Malawi-Liverpool-Wellcome Trust Clinical Research Programme, College of Medicine, University of Malawi, Blantyre, Malawi – sequence: 3 givenname: Jacqueline E surname: Tate fullname: Tate, Jacqueline E organization: Epidemiology Branch, Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control & Prevention, Atlanta, GA, USA – sequence: 4 givenname: Khuzwayo C surname: Jere fullname: Jere, Khuzwayo C organization: Malawi-Liverpool-Wellcome Trust Clinical Research Programme, College of Medicine, University of Malawi, Blantyre, Malawi – sequence: 5 givenname: Miren surname: Iturriza-Gomara fullname: Iturriza-Gomara, Miren organization: Institute of Infection and Global Health, University of Liverpool, Liverpool, UK – sequence: 6 givenname: Osamu surname: Nakagomi fullname: Nakagomi, Osamu organization: Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan – sequence: 7 givenname: Charles surname: Mwansambo fullname: Mwansambo, Charles organization: Ministry of Health & Population, Lilongwe, Malawi – sequence: 8 givenname: Anthony surname: Costello fullname: Costello, Anthony organization: Institute of Global Health, University College London, London, UK – sequence: 9 givenname: Umesh D surname: Parashar fullname: Parashar, Umesh D organization: Epidemiology Branch, Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control & Prevention, Atlanta, GA, USA – sequence: 10 givenname: Robert S surname: Heyderman fullname: Heyderman, Robert S organization: Malawi-Liverpool-Wellcome Trust Clinical Research Programme, College of Medicine, University of Malawi, Blantyre, Malawi – sequence: 11 givenname: Neil surname: French fullname: French, Neil organization: Malawi-Liverpool-Wellcome Trust Clinical Research Programme, College of Medicine, University of Malawi, Blantyre, Malawi – sequence: 12 givenname: Nigel A surname: Cunliffe fullname: Cunliffe, Nigel A email: n.a.cunliffe@liv.ac.uk organization: Institute of Infection and Global Health, University of Liverpool, Liverpool, UK |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25638521$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkttu1DAQhiNURA_wCCBL3JSLgJ04TgKiCFXlIBVxAVxbs86kuDj2YjtB-wi8NU625bASauVItsbf_2dmPIfZnnUWs-who08ZZeLZJ8brMi9p2x4z_qRmVNBc3MkOUpjnnFf13nLeIvvZYQiXlLLE8XvZflGJsqkKdpD9POt7VFFPaDEE4noCZHDWTWDQRuJdhEn7MZAJlNIWibbp68HGMB8_gIEfmkAf0ZO1dxcehgGiVklpTO7G-JyAJW4V0E8p7iyYFOiIgoC5cjYmjoQ4dpv72d0eTMAHV_tR9uXN2efTd_n5x7fvT1-f56qmdcwLbCtVti0vmWhKqGgqvO-gAYCKp9VQ3iJiRSularGivK96yusaUrjmCOVRdrL1XY-rATuVyvRg5NrrAfxGOtDy3xurv8oLN0le1pzRIhkcXxl4933EEOWgg0JjwKIbg2RCNIUQtGlvg9YlbwRnCX28g1660ad2LVTFGkqbJlGP_k7-d9bXD5qAF1tAeReCx14qHZfGp1q0kYzKeXzkMj5yng3JuFzGR4qkrnbU1z-4Sfdqq8P0cJNGL4PSaBV22qfpkp3TNzqc7Dgoo61WYL7hBsOfXshQSLo1mT3SPjvMBi__b3CLBH4BOBkGZA |
| CODEN | LANCAO |
| CitedBy_id | crossref_primary_10_1093_infdis_jiz084 crossref_primary_10_1128_JVI_01246_17 crossref_primary_10_1093_infdis_jiaa616 crossref_primary_10_1080_14760584_2019_1574224 crossref_primary_10_1093_aje_kwy097 crossref_primary_10_1186_s12879_018_3615_6 crossref_primary_10_1080_21645515_2018_1467202 crossref_primary_10_1016_S0140_6736_18_31128_0 crossref_primary_10_12688_wellcomeopenres_16174_2 crossref_primary_10_1093_infdis_jiz002 crossref_primary_10_1016_j_vaccine_2017_07_072 crossref_primary_10_1093_cid_civ1183 crossref_primary_10_1371_journal_pone_0154997 crossref_primary_10_1093_infdis_jiw524 crossref_primary_10_1111_tmi_13040 crossref_primary_10_1002_jmv_24664 crossref_primary_10_1093_cid_cix494 crossref_primary_10_1016_S2214_109X_15_00270_3 crossref_primary_10_1128_JCM_00875_15 crossref_primary_10_1016_j_vaccine_2019_04_023 crossref_primary_10_1179_2046905515Y_0000000014 crossref_primary_10_1002_jmv_24949 crossref_primary_10_1016_S1473_3099_20_30597_1 crossref_primary_10_1080_23120053_2018_1551850 crossref_primary_10_1093_tropej_fmy050 crossref_primary_10_1136_bmjopen_2017_017347 crossref_primary_10_1586_14787210_2015_1089171 crossref_primary_10_1016_j_vaccine_2016_07_001 crossref_primary_10_1016_j_vaccine_2018_07_007 crossref_primary_10_1093_infdis_jiw026 crossref_primary_10_1016_j_vaccine_2024_01_084 crossref_primary_10_3390_vaccines11101609 crossref_primary_10_1093_infdis_jix199 crossref_primary_10_1186_s12879_020_05230_0 crossref_primary_10_1080_21645515_2016_1231262 crossref_primary_10_1016_j_meegid_2018_12_004 crossref_primary_10_12688_wellcomeopenres_16174_1 crossref_primary_10_1016_j_chom_2019_05_006 crossref_primary_10_1016_j_cmi_2016_03_007 crossref_primary_10_1001_jamapediatrics_2021_0347 crossref_primary_10_1371_journal_pmed_1003655 crossref_primary_10_1016_j_jcv_2019_104248 crossref_primary_10_1016_S2214_109X_21_00165_0 crossref_primary_10_3390_pathogens8040210 crossref_primary_10_1016_j_vaccine_2017_01_072 crossref_primary_10_1016_j_vaccine_2016_10_077 crossref_primary_10_1016_S1473_3099_15_00227_3 crossref_primary_10_3390_vaccines6020028 crossref_primary_10_1016_j_meegid_2015_06_013 crossref_primary_10_1093_cid_civ256 crossref_primary_10_2807_1560_7917_ES_2019_24_6_1700774 crossref_primary_10_1007_s00705_015_2706_6 crossref_primary_10_1186_s13104_017_2883_3 crossref_primary_10_1111_1541_4337_12533 crossref_primary_10_1371_journal_pmed_1002298 crossref_primary_10_1016_j_jcvp_2024_100183 crossref_primary_10_1016_j_vaccine_2015_04_053 crossref_primary_10_1586_14760584_2015_1059282 crossref_primary_10_1093_aje_kwy163 crossref_primary_10_3201_eid2509_190258 crossref_primary_10_3390_v13122491 crossref_primary_10_1371_journal_pone_0172156 crossref_primary_10_1080_20469047_2015_1109245 crossref_primary_10_1016_j_vaccine_2018_04_030 crossref_primary_10_1016_j_vaccine_2018_06_026 crossref_primary_10_12688_wellcomeopenres_16224_2 crossref_primary_10_1126_scitranslmed_aav6419 crossref_primary_10_12688_wellcomeopenres_16224_1 crossref_primary_10_1080_21645515_2017_1356962 crossref_primary_10_1371_journal_pone_0168209 crossref_primary_10_1186_s12879_024_08979_w crossref_primary_10_1093_cid_ciz918 crossref_primary_10_1080_14760584_2018_1496825 crossref_primary_10_1371_journal_pone_0190256 crossref_primary_10_1093_cid_civ1014 crossref_primary_10_1099_mgen_0_000532 crossref_primary_10_1016_j_vaccine_2018_01_010 crossref_primary_10_1002_14651858_CD008521_pub4 crossref_primary_10_1371_journal_pone_0284934 crossref_primary_10_17352_jvi_000024 crossref_primary_10_1002_14651858_CD008521_pub5 crossref_primary_10_1080_21645515_2020_1776034 crossref_primary_10_1016_j_jhin_2015_12_010 crossref_primary_10_1016_j_vaccine_2018_02_058 crossref_primary_10_1186_s12879_017_2613_4 crossref_primary_10_1093_cid_ciy1067 crossref_primary_10_1136_bmjgh_2020_002669 crossref_primary_10_1097_INF_0000000000001828 crossref_primary_10_1016_j_vaccine_2017_08_091 crossref_primary_10_1080_14760584_2019_1622419 crossref_primary_10_1016_j_vaccine_2019_06_062 crossref_primary_10_1016_S1473_3099_21_00473_4 crossref_primary_10_1093_cid_civ1027 crossref_primary_10_12688_f1000research_11912_1 crossref_primary_10_1093_cid_ciw014 crossref_primary_10_1093_cid_civ1025 crossref_primary_10_1016_S2214_109X_18_30314_0 crossref_primary_10_1016_j_vaccine_2017_10_060 crossref_primary_10_1080_21645515_2018_1553593 crossref_primary_10_3390_vaccines11091507 crossref_primary_10_3390_vaccines10030418 crossref_primary_10_1080_19490976_2017_1376162 crossref_primary_10_1038_s41598_023_35681_9 crossref_primary_10_1177_2150131915622379 crossref_primary_10_1371_journal_pone_0244100 crossref_primary_10_1093_cid_ciy1096 crossref_primary_10_1016_j_vaccine_2019_09_022 crossref_primary_10_1080_14760584_2017_1371595 crossref_primary_10_3389_fmicb_2023_1297269 crossref_primary_10_1017_S0950268823000286 crossref_primary_10_1007_s13312_016_0889_x crossref_primary_10_1016_j_vaccine_2017_07_096 crossref_primary_10_1038_s41541_024_01008_6 crossref_primary_10_1016_j_vaccine_2018_02_077 crossref_primary_10_1016_S2214_109X_15_00318_6 crossref_primary_10_1080_21645515_2020_1859900 crossref_primary_10_1007_s12560_020_09426_0 crossref_primary_10_3201_eid2501_180782 crossref_primary_10_1093_cid_civ1207 crossref_primary_10_1016_j_vaccine_2018_10_068 crossref_primary_10_1080_21645515_2017_1323591 crossref_primary_10_1093_cid_ciz788 crossref_primary_10_1093_cid_civ1206 crossref_primary_10_1093_cid_civ1204 crossref_primary_10_1093_cid_ciz664 crossref_primary_10_1186_s13643_022_01947_y crossref_primary_10_1016_j_idc_2015_07_002 crossref_primary_10_1093_cid_cix369 crossref_primary_10_1093_ofid_ofy292 crossref_primary_10_3945_jn_116_243774 crossref_primary_10_1007_s40588_018_0079_9 crossref_primary_10_1093_infdis_jiw518 crossref_primary_10_1002_jmv_24531 |
| Cites_doi | 10.1016/S1473-3099(11)70253-5 10.1097/INF.0b013e3181fefb32 10.1179/2046905512Y.0000000015 10.1016/S0140-6736(10)60889-6 10.1136/bmj.e4752 10.1186/1471-2334-12-213 10.1016/j.vaccine.2008.08.034 10.1053/j.gastro.2009.07.046 10.1097/INF.0b013e3181d95b53 10.1056/NEJMoa0905211 10.1016/S0140-6736(10)60755-6 10.1111/1469-0691.12612 10.1097/INF.0b013e3181fefa05 10.1016/j.vaccine.2013.07.006 10.1186/1742-5573-6-1 10.1086/653577 10.1097/INF.0b013e3181fefdc0 10.1093/infdis/jir492 10.1086/649843 10.1016/j.ijid.2011.09.003 10.1186/1745-6215-12-151 10.1016/S1473-3099(14)70940-5 10.1056/NEJMoa0904797 10.3109/00365549009027046 10.1097/INF.0b013e3181fefc68 10.1093/cid/cis1010 |
| ContentType | Journal Article |
| Contributor | Crampin, Amelia C Phiri, Tambosi Lewycka, Sonia Beard, James Mvula, Hazzie Whitney, Cynthia G Verani, Jennifer R King, Carina |
| Contributor_xml | – sequence: 1 givenname: James surname: Beard fullname: Beard, James – sequence: 2 givenname: Amelia C surname: Crampin fullname: Crampin, Amelia C – sequence: 3 givenname: Carina surname: King fullname: King, Carina – sequence: 4 givenname: Sonia surname: Lewycka fullname: Lewycka, Sonia – sequence: 5 givenname: Hazzie surname: Mvula fullname: Mvula, Hazzie – sequence: 6 givenname: Tambosi surname: Phiri fullname: Phiri, Tambosi – sequence: 7 givenname: Jennifer R surname: Verani fullname: Verani, Jennifer R – sequence: 8 givenname: Cynthia G surname: Whitney fullname: Whitney, Cynthia G |
| Copyright | 2015 Bar-Zeev, et al. Open Access article distributed under the terms of CC BY Bar-Zeev, et al. Open Access article distributed under the terms of CC BY Copyright © 2015 Bar-Zeev, et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Apr 2015 2015 Bar-Zeev, et al. Open Access article distributed under the terms of CC BY 2015 |
| Copyright_xml | – notice: 2015 Bar-Zeev, et al. Open Access article distributed under the terms of CC BY – notice: Bar-Zeev, et al. Open Access article distributed under the terms of CC BY – notice: Copyright © 2015 Bar-Zeev, et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Apr 2015 – notice: 2015 Bar-Zeev, et al. Open Access article distributed under the terms of CC BY 2015 |
| CorporateAuthor | for the VacSurv Consortium VacSurv Consortium |
| CorporateAuthor_xml | – name: for the VacSurv Consortium – name: VacSurv Consortium |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 0TZ 3V. 7QL 7RV 7U9 7X7 7XB 88E 8AO 8C1 8C2 8FI 8FJ 8FK ABUWG AEUYN AFKRA BENPR C1K CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P M7N NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM |
| DOI | 10.1016/S1473-3099(14)71060-6 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Pharma and Biotech Premium PRO ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & allied health premium. Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Lancet Titles Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Environmental Sciences and Pollution Management ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Proquest Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Pharma and Biotech Premium PRO ProQuest One Academic Middle East (New) Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection Environmental Sciences and Pollution Management ProQuest Central ProQuest One Sustainability Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic AIDS and Cancer Research Abstracts Pharma and Biotech Premium PRO |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1474-4457 |
| EndPage | 428 |
| ExternalDocumentID | PMC4374102 3632286421 25638521 10_1016_S1473_3099_14_71060_6 S1473309914710606 1_s2_0_S1473309914710606 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Malawi Asia |
| GeographicLocations_xml | – name: Malawi – name: Asia |
| GrantInformation | Wellcome Trust, GlaxoSmithKline Biologicals. |
| GrantInformation_xml | – fundername: Wellcome Trust grantid: 098610 – fundername: Wellcome Trust grantid: 091909/Z/10/Z |
| GroupedDBID | --- --K --M -RU ..I .1- .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4G. 53G 5VS 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8C2 8FI 8FJ AAAJQ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AARKO AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABJNI ABMAC ABMZM ABUWG ABWVN ACGFS ACIEU ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGEKW AGHFR AGQPQ AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CJTIS CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA HF~ HMCUK HVGLF HZ~ IHE J1W KOM M1P M41 MO0 N9A NAPCQ O-L O9- OD- OO. OZT P-8 P-9 P2P PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO R2- ROL RPZ SDG SEL SES SPCBC SSH SSI SSZ T5K TLN UKHRP UV1 WOW XBR Z5R 3V. AACTN AAYOK AFCTW AFKWA AJOXV ALIPV AMFUW RIG SDF 6I. AAFTH ABLVK ABYKQ AJBFU ZA5 AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 0TZ 7QL 7U9 7XB 8FK C1K H94 K9. M7N PKEHL PQEST PQUKI 7X8 ACLOT ~HD 5PM |
| ID | FETCH-LOGICAL-c707t-2e95c399431683a50060fda8aaa545458049eee505cc76b04f5f0477a49e74ea3 |
| IEDL.DBID | 7X7 |
| ISSN | 1473-3099 1474-4457 |
| IngestDate | Thu Aug 21 14:07:29 EDT 2025 Sat Sep 27 20:55:17 EDT 2025 Sat Sep 27 19:11:23 EDT 2025 Sat Jul 26 01:18:50 EDT 2025 Mon Jul 21 05:49:21 EDT 2025 Tue Jul 01 01:42:46 EDT 2025 Thu Apr 24 23:04:22 EDT 2025 Fri Feb 23 02:26:59 EST 2024 Sun Feb 23 10:19:07 EST 2025 Tue Aug 26 17:35:24 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| License | http://creativecommons.org/licenses/by/4.0 Copyright © 2015 Bar-Zeev, et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd. All rights reserved. This work is licensed under a Creative Commons Attribution 4.0 International License, which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c707t-2e95c399431683a50060fda8aaa545458049eee505cc76b04f5f0477a49e74ea3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Members listed at end of paper |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC4374102 |
| PMID | 25638521 |
| PQID | 1665180088 |
| PQPubID | 44001 |
| PageCount | 7 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4374102 proquest_miscellaneous_1668266089 proquest_miscellaneous_1667348641 proquest_journals_1665180088 pubmed_primary_25638521 crossref_citationtrail_10_1016_S1473_3099_14_71060_6 crossref_primary_10_1016_S1473_3099_14_71060_6 elsevier_sciencedirect_doi_10_1016_S1473_3099_14_71060_6 elsevier_clinicalkeyesjournals_1_s2_0_S1473309914710606 elsevier_clinicalkey_doi_10_1016_S1473_3099_14_71060_6 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2015-04-01 |
| PublicationDateYYYYMMDD | 2015-04-01 |
| PublicationDate_xml | – month: 04 year: 2015 text: 2015-04-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: London |
| PublicationTitle | The Lancet infectious diseases |
| PublicationTitleAlternate | Lancet Infect Dis |
| PublicationYear | 2015 |
| Publisher | Elsevier Ltd Elsevier Limited Elsevier Science ;, The Lancet Pub. Group |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited – name: Elsevier Science ;, The Lancet Pub. Group |
| References | Cortese, Tate, Simonsen, Edelman, Parashar (bib3) 2010; 29 (bib13) 2009; 84 Tate, Burton, Boschi-Pinto, Steele, Duque, Parashar (bib1) 2012; 12 Zaman, Dang, Victor (bib12) 2010; 376 Hanquet, Valenciano, Simondon, Moren (bib22) 2013; 31 (bib18) 2011 Gurgel, Bohland, Vieira (bib4) 2009; 137 Bayard, DeAntonio, Contreras (bib9) 2012; 16 Turner, Ngwira, Witte, Mwapasa, Dove, Cunliffe (bib27) 2013; 33 Braeckman, Van Herck, Meyer (bib29) 2012; 345 Armah, Sow, Breiman (bib11) 2010; 376 Lopman, Curns, Yen, Parashar (bib33) 2011; 204 (bib19) 2009 (bib15) 2012 Pagel, Prost, Lewycka (bib21) 2011; 12 Steele, De Vos, Tumbo (bib25) 2010; 28 (bib14) 2014 Ruuska, Vesikari (bib17) 1990; 22 Hothorn, Vaeth, Hothorn (bib23) 2009; 6 Yen, Armero Guardado, Alberto (bib8) 2011; 30 Correia, Patel, Nakagomi (bib31) 2010; 201 Cunliffe, Ngwira, Dove (bib26) 2010; 202 Anderson, Shippee, Weinrobe (bib32) 2013; 56 Quintanar-Solares, Yen, Richardson, Esparza-Aguilar, Parashar, Patel (bib6) 2011; 30 Molto, Cortes, De Oliveira (bib5) 2011; 30 Tate, Cortese, Payne (bib7) 2011; 30 Madhi, Cunliffe, Steele (bib10) 2010; 362 Groome, Page, Cortese (bib24) 2014; 14 (bib16) 2013 Steele, Neuzil, Cunliffe (bib30) 2012; 12 (bib20) 2009 Matthijnssens, Zeller, Heylen (bib28) 2014; 20 Richardson, Hernandez-Pichardo, Quintanar-Solares (bib2) 2010; 362 (10.1016/S1473-3099(14)71060-6_bib19) 2009 Braeckman (10.1016/S1473-3099(14)71060-6_bib29) 2012; 345 Cunliffe (10.1016/S1473-3099(14)71060-6_bib26) 2010; 202 Steele (10.1016/S1473-3099(14)71060-6_bib25) 2010; 28 Pagel (10.1016/S1473-3099(14)71060-6_bib21) 2011; 12 Yen (10.1016/S1473-3099(14)71060-6_bib8) 2011; 30 Cortese (10.1016/S1473-3099(14)71060-6_bib3) 2010; 29 (10.1016/S1473-3099(14)71060-6_bib18) 2011 Matthijnssens (10.1016/S1473-3099(14)71060-6_bib28) 2014; 20 Tate (10.1016/S1473-3099(14)71060-6_bib7) 2011; 30 Molto (10.1016/S1473-3099(14)71060-6_bib5) 2011; 30 Lopman (10.1016/S1473-3099(14)71060-6_bib33) 2011; 204 Groome (10.1016/S1473-3099(14)71060-6_bib24) 2014; 14 Armah (10.1016/S1473-3099(14)71060-6_bib11) 2010; 376 Anderson (10.1016/S1473-3099(14)71060-6_bib32) 2013; 56 Madhi (10.1016/S1473-3099(14)71060-6_bib10) 2010; 362 (10.1016/S1473-3099(14)71060-6_bib20) 2009 Steele (10.1016/S1473-3099(14)71060-6_bib30) 2012; 12 Tate (10.1016/S1473-3099(14)71060-6_bib1) 2012; 12 Turner (10.1016/S1473-3099(14)71060-6_bib27) 2013; 33 Bayard (10.1016/S1473-3099(14)71060-6_bib9) 2012; 16 (10.1016/S1473-3099(14)71060-6_bib13) 2009; 84 Gurgel (10.1016/S1473-3099(14)71060-6_bib4) 2009; 137 Zaman (10.1016/S1473-3099(14)71060-6_bib12) 2010; 376 Quintanar-Solares (10.1016/S1473-3099(14)71060-6_bib6) 2011; 30 Hanquet (10.1016/S1473-3099(14)71060-6_bib22) 2013; 31 Richardson (10.1016/S1473-3099(14)71060-6_bib2) 2010; 362 Ruuska (10.1016/S1473-3099(14)71060-6_bib17) 1990; 22 Correia (10.1016/S1473-3099(14)71060-6_bib31) 2010; 201 Hothorn (10.1016/S1473-3099(14)71060-6_bib23) 2009; 6 25638520 - Lancet Infect Dis. 2015 Apr;15(4):368-70. doi: 10.1016/S1473-3099(14)71089-8. |
| References_xml | – volume: 14 start-page: 1096 year: 2014 end-page: 1104 ident: bib24 article-title: Effectiveness of monovalent human rotavirus vaccine against admission to hospital for acute rotavirus diarrhoea in South African children: a case-control study publication-title: Lancet Infect Dis – volume: 30 start-page: S16 year: 2011 end-page: S20 ident: bib5 article-title: Reduction of diarrhea-associated hospitalizations among children aged <5 years in Panama following the introduction of rotavirus vaccine publication-title: Pediatr Infect Dis J – year: 2009 ident: bib20 publication-title: Malawi census of population and housing 2008 – volume: 33 start-page: 42 year: 2013 end-page: 45 ident: bib27 article-title: Surveillance of rotavirus gastro-enteritis in children in Blantyre, Malawi publication-title: Paediatr Int Child Health – volume: 376 start-page: 606 year: 2010 end-page: 614 ident: bib11 article-title: Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial publication-title: Lancet – volume: 22 start-page: 259 year: 1990 end-page: 267 ident: bib17 article-title: Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes publication-title: Scand J Infect Dis – volume: 30 start-page: S56 year: 2011 end-page: S60 ident: bib7 article-title: Uptake, impact, and effectiveness of rotavirus vaccination in the United States: review of the first 3 years of postlicensure data publication-title: Pediatr Infect Dis J – volume: 29 start-page: 489 year: 2010 end-page: 494 ident: bib3 article-title: Reduction in gastroenteritis in United States children and correlation with early rotavirus vaccine uptake from national medical claims databases publication-title: Pediatr Infect Dis J – year: 2014 ident: bib14 article-title: Rotavirus Vaccine Access and Delivery – volume: 204 start-page: 980 year: 2011 end-page: 986 ident: bib33 article-title: Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States publication-title: J Infect Dis – volume: 84 start-page: 220 year: 2009 end-page: 236 ident: bib13 article-title: Meeting of the immunization Strategic Advisory Group of Experts, April 2009–conclusions and recommendations publication-title: Wkly Epidemiol Rec – volume: 345 start-page: e4752 year: 2012 ident: bib29 article-title: Effectiveness of rotavirus vaccination in prevention of hospital admissions for rotavirus gastroenteritis among young children in Belgium: case-control study publication-title: BMJ – volume: 28 start-page: 6542 year: 2010 end-page: 6548 ident: bib25 article-title: Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines publication-title: Vaccine – year: 2013 ident: bib16 article-title: GINI index data table – year: 2009 ident: bib19 publication-title: Department of immunizations vaccines and biologicals. A manual of rotavirus detection and characterization methods – year: 2011 ident: bib18 publication-title: Malawi Integrated guidelines for providing HIV services – volume: 137 start-page: 1970 year: 2009 end-page: 1975 ident: bib4 article-title: Incidence of rotavirus and all-cause diarrhea in northeast Brazil following the introduction of a national vaccination program publication-title: Gastroenterology – volume: 6 start-page: 1 year: 2009 end-page: 10 ident: bib23 article-title: Trend tests for the evaluation of exposure-response relationships in epidemiological exposure studies publication-title: Epidemiol Perspect Innov – volume: 56 start-page: 755 year: 2013 end-page: 760 ident: bib32 article-title: Indirect protection of adults from rotavirus by pediatric rotavirus vaccination publication-title: Clin Infect Dis – volume: 376 start-page: 615 year: 2010 end-page: 623 ident: bib12 article-title: Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial publication-title: Lancet – volume: 31 start-page: 5634 year: 2013 end-page: 5642 ident: bib22 article-title: Vaccine effects and impact of vaccination programmes in post-licensure studies publication-title: Vaccine – volume: 16 start-page: e94 year: 2012 end-page: e98 ident: bib9 article-title: Impact of rotavirus vaccination on childhood gastroenteritis-related mortality and hospital discharges in Panama publication-title: Int J Infect Dis – volume: 20 start-page: O702 year: 2014 end-page: O710 ident: bib28 article-title: Higher proportion of G2P[4] rotaviruses in vaccinated hospitalized cases compared with unvaccinated hospitalized cases, despite high vaccine effectiveness against heterotypic G2P[4] rotaviruses publication-title: Clin Microbiol Infect – volume: 12 start-page: 213 year: 2012 end-page: 220 ident: bib30 article-title: Human rotavirus vaccine Rotarix™ provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial publication-title: BMC Infect Dis – volume: 30 start-page: S11 year: 2011 end-page: S15 ident: bib6 article-title: Impact of rotavirus vaccination on diarrhea-related hospitalizations among children <5 years of age in Mexico publication-title: Pediatr Infect Dis J – volume: 30 start-page: S6 year: 2011 end-page: 10 ident: bib8 article-title: Decline in rotavirus hospitalizations and health care visits for childhood diarrhea following rotavirus vaccination in El Salvador publication-title: Pediatr Infect Dis J – volume: 12 start-page: 151 year: 2011 ident: bib21 article-title: Intracluster correlation coefficients and coefficients of variation for perinatal outcomes from five cluster-randomised controlled trials in low and middle-income countries: results and methodological implications publication-title: Trials – volume: 362 start-page: 299 year: 2010 end-page: 305 ident: bib2 article-title: Effect of rotavirus vaccination on death from childhood diarrhea in Mexico publication-title: N Engl J Med – volume: 201 start-page: 363 year: 2010 end-page: 369 ident: bib31 article-title: Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil publication-title: J Infect Dis – volume: 362 start-page: 289 year: 2010 end-page: 298 ident: bib10 article-title: Effect of human rotavirus vaccine on severe diarrhea in African infants publication-title: N Engl J Med – volume: 12 start-page: 136 year: 2012 end-page: 141 ident: bib1 article-title: 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis publication-title: Lancet Infect Dis – volume: 202 start-page: S168 year: 2010 end-page: S174 ident: bib26 article-title: Epidemiology of rotavirus infection in children in Blantyre, Malawi, 1997–2007 publication-title: J Infect Dis – year: 2012 ident: bib15 article-title: Malawi Statistics – year: 2009 ident: 10.1016/S1473-3099(14)71060-6_bib20 – volume: 12 start-page: 136 year: 2012 ident: 10.1016/S1473-3099(14)71060-6_bib1 article-title: 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(11)70253-5 – volume: 30 start-page: S11 year: 2011 ident: 10.1016/S1473-3099(14)71060-6_bib6 article-title: Impact of rotavirus vaccination on diarrhea-related hospitalizations among children <5 years of age in Mexico publication-title: Pediatr Infect Dis J doi: 10.1097/INF.0b013e3181fefb32 – volume: 33 start-page: 42 year: 2013 ident: 10.1016/S1473-3099(14)71060-6_bib27 article-title: Surveillance of rotavirus gastro-enteritis in children in Blantyre, Malawi publication-title: Paediatr Int Child Health doi: 10.1179/2046905512Y.0000000015 – volume: 376 start-page: 606 year: 2010 ident: 10.1016/S1473-3099(14)71060-6_bib11 article-title: Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(10)60889-6 – volume: 345 start-page: e4752 year: 2012 ident: 10.1016/S1473-3099(14)71060-6_bib29 article-title: Effectiveness of rotavirus vaccination in prevention of hospital admissions for rotavirus gastroenteritis among young children in Belgium: case-control study publication-title: BMJ doi: 10.1136/bmj.e4752 – volume: 12 start-page: 213 year: 2012 ident: 10.1016/S1473-3099(14)71060-6_bib30 article-title: Human rotavirus vaccine Rotarix™ provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial publication-title: BMC Infect Dis doi: 10.1186/1471-2334-12-213 – volume: 84 start-page: 220 year: 2009 ident: 10.1016/S1473-3099(14)71060-6_bib13 article-title: Meeting of the immunization Strategic Advisory Group of Experts, April 2009–conclusions and recommendations publication-title: Wkly Epidemiol Rec – volume: 28 start-page: 6542 year: 2010 ident: 10.1016/S1473-3099(14)71060-6_bib25 article-title: Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines publication-title: Vaccine doi: 10.1016/j.vaccine.2008.08.034 – volume: 137 start-page: 1970 year: 2009 ident: 10.1016/S1473-3099(14)71060-6_bib4 article-title: Incidence of rotavirus and all-cause diarrhea in northeast Brazil following the introduction of a national vaccination program publication-title: Gastroenterology doi: 10.1053/j.gastro.2009.07.046 – year: 2009 ident: 10.1016/S1473-3099(14)71060-6_bib19 – volume: 29 start-page: 489 year: 2010 ident: 10.1016/S1473-3099(14)71060-6_bib3 article-title: Reduction in gastroenteritis in United States children and correlation with early rotavirus vaccine uptake from national medical claims databases publication-title: Pediatr Infect Dis J doi: 10.1097/INF.0b013e3181d95b53 – volume: 362 start-page: 299 year: 2010 ident: 10.1016/S1473-3099(14)71060-6_bib2 article-title: Effect of rotavirus vaccination on death from childhood diarrhea in Mexico publication-title: N Engl J Med doi: 10.1056/NEJMoa0905211 – volume: 376 start-page: 615 year: 2010 ident: 10.1016/S1473-3099(14)71060-6_bib12 article-title: Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(10)60755-6 – volume: 20 start-page: O702 year: 2014 ident: 10.1016/S1473-3099(14)71060-6_bib28 article-title: Higher proportion of G2P[4] rotaviruses in vaccinated hospitalized cases compared with unvaccinated hospitalized cases, despite high vaccine effectiveness against heterotypic G2P[4] rotaviruses publication-title: Clin Microbiol Infect doi: 10.1111/1469-0691.12612 – volume: 30 start-page: S6 year: 2011 ident: 10.1016/S1473-3099(14)71060-6_bib8 article-title: Decline in rotavirus hospitalizations and health care visits for childhood diarrhea following rotavirus vaccination in El Salvador publication-title: Pediatr Infect Dis J doi: 10.1097/INF.0b013e3181fefa05 – volume: 31 start-page: 5634 year: 2013 ident: 10.1016/S1473-3099(14)71060-6_bib22 article-title: Vaccine effects and impact of vaccination programmes in post-licensure studies publication-title: Vaccine doi: 10.1016/j.vaccine.2013.07.006 – volume: 6 start-page: 1 year: 2009 ident: 10.1016/S1473-3099(14)71060-6_bib23 article-title: Trend tests for the evaluation of exposure-response relationships in epidemiological exposure studies publication-title: Epidemiol Perspect Innov doi: 10.1186/1742-5573-6-1 – volume: 202 start-page: S168 issue: suppl year: 2010 ident: 10.1016/S1473-3099(14)71060-6_bib26 article-title: Epidemiology of rotavirus infection in children in Blantyre, Malawi, 1997–2007 publication-title: J Infect Dis doi: 10.1086/653577 – volume: 30 start-page: S56 year: 2011 ident: 10.1016/S1473-3099(14)71060-6_bib7 article-title: Uptake, impact, and effectiveness of rotavirus vaccination in the United States: review of the first 3 years of postlicensure data publication-title: Pediatr Infect Dis J doi: 10.1097/INF.0b013e3181fefdc0 – volume: 204 start-page: 980 year: 2011 ident: 10.1016/S1473-3099(14)71060-6_bib33 article-title: Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States publication-title: J Infect Dis doi: 10.1093/infdis/jir492 – volume: 201 start-page: 363 year: 2010 ident: 10.1016/S1473-3099(14)71060-6_bib31 article-title: Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil publication-title: J Infect Dis doi: 10.1086/649843 – year: 2011 ident: 10.1016/S1473-3099(14)71060-6_bib18 – volume: 16 start-page: e94 year: 2012 ident: 10.1016/S1473-3099(14)71060-6_bib9 article-title: Impact of rotavirus vaccination on childhood gastroenteritis-related mortality and hospital discharges in Panama publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2011.09.003 – volume: 12 start-page: 151 year: 2011 ident: 10.1016/S1473-3099(14)71060-6_bib21 article-title: Intracluster correlation coefficients and coefficients of variation for perinatal outcomes from five cluster-randomised controlled trials in low and middle-income countries: results and methodological implications publication-title: Trials doi: 10.1186/1745-6215-12-151 – volume: 14 start-page: 1096 year: 2014 ident: 10.1016/S1473-3099(14)71060-6_bib24 article-title: Effectiveness of monovalent human rotavirus vaccine against admission to hospital for acute rotavirus diarrhoea in South African children: a case-control study publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(14)70940-5 – volume: 362 start-page: 289 year: 2010 ident: 10.1016/S1473-3099(14)71060-6_bib10 article-title: Effect of human rotavirus vaccine on severe diarrhea in African infants publication-title: N Engl J Med doi: 10.1056/NEJMoa0904797 – volume: 22 start-page: 259 year: 1990 ident: 10.1016/S1473-3099(14)71060-6_bib17 article-title: Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes publication-title: Scand J Infect Dis doi: 10.3109/00365549009027046 – volume: 30 start-page: S16 year: 2011 ident: 10.1016/S1473-3099(14)71060-6_bib5 article-title: Reduction of diarrhea-associated hospitalizations among children aged <5 years in Panama following the introduction of rotavirus vaccine publication-title: Pediatr Infect Dis J doi: 10.1097/INF.0b013e3181fefc68 – volume: 56 start-page: 755 year: 2013 ident: 10.1016/S1473-3099(14)71060-6_bib32 article-title: Indirect protection of adults from rotavirus by pediatric rotavirus vaccination publication-title: Clin Infect Dis doi: 10.1093/cid/cis1010 – reference: 25638520 - Lancet Infect Dis. 2015 Apr;15(4):368-70. doi: 10.1016/S1473-3099(14)71089-8. |
| SSID | ssj0017104 |
| Score | 2.5282235 |
| Snippet | Rotavirus is the main cause of severe acute gastroenteritis in children in Africa. Monovalent human rotavirus vaccine (RV1) was added into Malawi's infant... Summary Background Rotavirus is the main cause of severe acute gastroenteritis in children in Africa. Monovalent human rotavirus vaccine (RV1) was added into... Background Rotavirus is the main cause of severe acute gastroenteritis in children in Africa. Monovalent human rotavirus vaccine (RV1) was added into Malawi's... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 422 |
| SubjectTerms | Case-Control Studies Child, Preschool Diarrhea Feces - virology Female Gastroenteritis Gastroenteritis - epidemiology Gastroenteritis - prevention & control Genotypes Hospitals Human rotavirus Humans Immunization Incidence Infant Infant, Newborn Infants Infectious Disease Infectious diseases Laboratories Malawi - epidemiology Male Mortality Rotavirus Rotavirus Infections - epidemiology Rotavirus Infections - prevention & control Rotavirus Vaccines - administration & dosage Rotavirus Vaccines - immunology Treatment Outcome Vaccines Vaccines, Attenuated - administration & dosage Vaccines, Attenuated - immunology |
| Title | Effectiveness of a monovalent rotavirus vaccine in infants in Malawi after programmatic roll-out: an observational and case-control study |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1473309914710606 https://www.clinicalkey.es/playcontent/1-s2.0-S1473309914710606 https://dx.doi.org/10.1016/S1473-3099(14)71060-6 https://www.ncbi.nlm.nih.gov/pubmed/25638521 https://www.proquest.com/docview/1665180088 https://www.proquest.com/docview/1667348641 https://www.proquest.com/docview/1668266089 https://pubmed.ncbi.nlm.nih.gov/PMC4374102 |
| Volume | 15 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bb9MwFLZgkxASQjBuhTEZiQd4MIsTx3Z5QTBtmpA6IWBS3yzHsbVKVTKadPsN-9ccO47HuGxIVVsl_pK0xz7ns30uCL3Oqmmdg84jxtKaMDtlRMqakkKHbG4OzIaPRp4d8cNj9nlezuOCWxfdKkedGBR13Rq_Rr5LOS8psBspP5z-IL5qlN9djSU0bqNNCkzEl24Q8zThomA9w64yEwUpgApdRvDsfksH31D2FhpymEX9yzb9yT1_d6H8xSYdPED3I5nEHwfpP0S3bLOF7szidvkWujcsyuEh1ugRuhhyFUcFh1uHNYbf1UJvgxvgVdvrs8Vq3eEzbfwV8KKBl_OuMv7rTC_1-QKHsuI4OnaFjK-AXC5Ju-7fY93gtkorvfBwuqmxAVNJolM8DgltH6Pjg_3ve4ck1mIgRmSiJ7mdlgbIjI-cl4Uvo8AzV2uptQYOxkoJMw1rLfApYwSvMuZKlzEhNBwWzOriCdpo2sY-Q9iZqpClYwaYBKu4lM652ocEG2rLXNMJYqMUlImJyn29jKVKHmleeMoLD2YuKghP8Ql6l2CnQ6aOmwB8FLEaw1BBcSqwJTcBxd-AtovDv1NUdbnKBrQHw6eHAlImZGQ4A3P5n5tuj71QXd4nDYoJepVOg4Lwuz66se06tPEZjDij17aBaSbP5HSCng4dO_2HwIlBXDmgxZUunxr4BOVXzzSLk5ConBXAV7P8-fWP_gLdBRZaDu5Q22ijX63tS2B6fbUThjO8yz26gzY_7R99-foTVpRPoQ |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1baxQxFA61ggoiWi9drRpBQR9i55LJZAURqZat7fbFFvoWM5kEF5aZdne2xZ_gn_E3ek5mJrVeWl8KC7PM5JsMczLnfEnOhZDnUTEsE9B5zNi4ZNwOOZOyjFmqfTY3B2YDo5HHu2K0zz8dZAdL5EcfC4Nulb1O9Iq6rA2uka_HQmQxsBsp3x0eMawahburfQmNdlhs228nMGWbv936APJ9kSSbH_c2RqyrKsBMHuUNS-wwM2CWMQZcplgQQESu1FJrDWyCZxI4s7UWmIExuSgi7jIX8TzXcDrnVqdw3yvkKkYaYa5-uRFcSmKw1n4Xm-cpS4F6nUYMrX8OJ1_G_BU0FDBr-5ct_JPr_u6y-YsN3LxNbnXklb5vR9sdsmSrFXJt3G3Pr5Cb7SIgbWOb7pLvbW7kTqHS2lFN4T3WMLqhAzqrG308mS3m9FgbvAOdVPBz6JqDf8d6qk8m1Jcxp50jmc8wC8jplNWL5g3VFa2LsLIMD6erkhowzaxzwqc-ge49sn8pUrpPlqu6squEOlOkMnPcAHPhhZDSOVdiCLKJbZboeEB4LwVlusToWJ9jqoIHHApPofBgpqS88JQYkNcBdthmBrkIIHoRqz7sFRS1Att1ETD_G9DOO3UzV7GaJypq0QiGI0IBKQOyY1QtU_qfTtf6UahO-wkf4YA8C5dBIeEuk65svfBtMGOS4PG5bWBaKyI5HJAH7cAO7xA4OIgrAXR-ZsiHBpgQ_eyVavLVJ0bnKfDjKHl4_qM_JddHe-MdtbO1u_2I3AAGnLWuWGtkuZkt7GNgmU3xxH_alHy5bF3yE8e_iKQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1baxQxFA61hSKIaL2tVo2goA9p55LJzApF1La01l2KWuhbzGQSXFhm6l5a_An-NX-VX2YyU-ul9aWwMMtMTjLkZM75TnIuhDwN8n4RQeYxbcKCcdPnLMuKkMWqzuZmoTZcNPJgKHYO-LvD5HCB_GhjYZxbZSsTa0FdVNrtka-HQiQh0A0MNuvdIvY3t18dfWWugpQ7aW3LaShfZqHYqNON-SCPPfPtBObcdGN3E7x_FkXbW5_e7jBfcYDpNEhnLDL9RENlu_jwLHbFAkRgC5UppYA0eJIBTxtjgBq0TkUecJvYgKepwu2UGxWj3ytkKUUXMASX3mwN9z90ZxrQ5fUZN09jFgOYncYTrX_sbj4P-Qs0FLDp_qUp_0TCvzt0_qIht2-Q6x7a0tfNWrxJFky5QpYH_vB-hVxrtghpE_l0i3xvMid7cUsrSxXFzFZY-xiATqqZOh5N5lN6jLlGD3RU4med4477O1BjdTKidZFz6t3M6vyzoByPWTWfvaSqpFXe7Tvj5VRZUA3FzbyLPq3T694mB5fCpztksaxKc49Qq_M4SyzXwDU8F1lmrS1cgLIOTRKpsEd4ywWpfdp0V71jLDv_OMc86ZgHO0rWzJOiR9Y6sqMmb8hFBKJlsWyDYiHGJTTbRYTp3wjN1AujqQzlNJJBQ-2IcXWkoMw6So-3Ghz1P4OutqtQno7TfaI98qR7DHHlzqBUaap53cblUxI8PLcNjF4RZP0eudss7G4OgdDBrgjU6Zkl3zVw6dLPPilHX-q06TwGeg6i--e_-mOyDLki3-8O9x6Qq4DHSeOntUoWZ5O5eQgIOssf-W-bks-XLU5-AlGck7Q |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effectiveness+of+a+monovalent+rotavirus+vaccine+in+infants+in+Malawi+after+programmatic+roll-out%3A+an+observational+and+case-control+study&rft.jtitle=The+Lancet+infectious+diseases&rft.au=Bar-Zeev%2C+Naor&rft.au=Kapanda%2C+Lester&rft.au=Tate%2C+Jacqueline+E&rft.au=Jere%2C+Khuzwayo+C&rft.date=2015-04-01&rft.issn=1473-3099&rft.volume=15&rft.issue=4&rft.spage=422&rft.epage=428&rft_id=info:doi/10.1016%2FS1473-3099%2814%2971060-6&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_S1473_3099_14_71060_6 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14733099%2FS1473309915X70800%2Fcov150h.gif |